Almonty's Q3 Beat Comes With a Discount: Stifel Trims Its Target as Sangdong Faces Its First Real Test
Published on 11/13/2026 at 17:41 | Editorial boerse-global.de
Almonty's first tungsten concentrate out of Sangdong since 1993 landed alongside a C$41.9 million quarterly revenue print — a 382% year-over-year jump — yet the market's attention is fixed less on the milestone than on what it cost to get there and what comes next. Stifel responded by trimming its price target to US$18 from US$21 while keeping its Buy rating intact, a signal that conviction in the story survives even as the valuation math gets tighter.
The quarter itself was a study in contrasts. Adjusted EBITDA came in at C$14.6 million, set against selling and administrative expenses of C$11.6 million. Net income rose 51% to C$50.2 million, but C$47.9 million of that figure consisted of non-cash revaluation gains — meaning the bulk of the reported bottom line reflected paper adjustments rather than cash generation. Revenue also fell short of Stifel's C$44.9 million estimate, a miss that puts the quality of expectations under the microscope.
A Lower Multiple, Not a Lower Conviction
The more telling detail sits in the valuation methodology. Stifel now applies 11.5 times its estimated 2027 EBITDA, down from a 12.5x factor previously. That shift — rather than any change in the growth outlook — accounts for the target cut. The analysts continue to see upside, provided costs and timing don't erode the economics of the ramp-up.
Sangdong is the fulcrum on which that case rests. Stifel considers roughly C$30 million in revenue from the mine plausible for the final quarter of the year, and has indicated that a slight slip into 2027 would not materially alter its investment thesis. Full production capacity is targeted for 2027. For shareholders, the duration of any delay matters as much as its cause — and the tolerance embedded in the Buy rating has limits.
Should investors sell immediately? Or is it worth buying Almonty?
CEO Lewis Black made the strategic argument in his Sunday newsletter, addressing the Sangdong commissioning progress, the Gentung project in Montana, and concerns over tungsten supply chains. The pitch is straightforward: tungsten sourced outside China carries strategic weight. Whether that argument translates into shareholder value depends on Almonty converting demand into operating income at a cost the market will reward. Strategic relevance and operational execution have to meet in the same place.
A C$67 Million Claim Lands in Court
Running parallel to the production story is a legal dispute with Deutsche Rohstoff. The German company disclosed Wednesday that it has sued Almonty in Canada, seeking approximately US$67 million tied to 3.5 million conversion shares and the repayment of debt. Almonty has filed a related claim of its own, and the two proceedings have been consolidated. The amounts asserted are Deutsche Rohstoff's claims, not judicial findings.
The shares climbed 6.0% on the day the quarterly figures were released, suggesting investors initially weighted the Sangdong milestone more heavily than either the revenue miss or the litigation. That reaction, however, came before the full weight of the court claim had settled into the narrative.
Almonty at a turning point? This analysis reveals what investors need to know now.
What emerges is a company whose strategic case — non-Chinese tungsten supply — remains intact, but whose valuation now hinges on execution at Sangdong and on how reliably rising revenue converts into higher operating profit. The first concentrate since 1993 is a genuine operational marker. The next several quarters will determine whether it becomes the foundation of an earnings story or merely a footnote in one.
Ad
Almonty Stock: New Analysis - 13 November
Fresh Almonty information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
